Literature DB >> 17762453

Work disability and health system utilization in patients with fibromyalgia syndrome.

A W Al-Allaf1.   

Abstract

BACKGROUND: Fibromyalgia syndrome (FMS) usually affects women of working age. We expect significant work-related disability in association with FMS. Because of the variety of symptoms, these patients often have multiple visits to their general practitioners with many referrals and visits to various specialists.
OBJECTIVE: To investigate the impact of fibromyalgia on working disability and health system utilization.
METHOD: This was a case-control study comparing fibromyalgia outpatient attendees with controls attending nonrheumatology outpatient clinics in Eastern Scotland. One hundred thirty-six patients with FMS and 152 age- and sex-matched controls completed a postal questionnaire about their working history and attendance at various outpatient clinics and general practitioners' visits.
RESULTS: Significant number of patients with FMS (46.8%) reported that they lost their job because of the disease, compared with only 14.1% of controls (P < 0.00001). There was no significant difference in health system utilization between patients with FMS and other clinic controls in a subset of patients surveyed.
CONCLUSION: Fibromyalgia is significantly associated with reports of working disability. Reasons for this decreased employment need to be investigated. The impact on the health system appeared to be the same as for patients with known specific organic diseases with regard to the number of general practitioner or hospital visits.

Entities:  

Mesh:

Year:  2007        PMID: 17762453     DOI: 10.1097/RHU.0b013e31812e6b0c

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  13 in total

Review 1.  Fibromyalgia: disease synopsis, medication cost effectiveness and economic burden.

Authors:  Tracy L Skaer
Journal:  Pharmacoeconomics       Date:  2014-05       Impact factor: 4.981

Review 2.  Societal and patient burden of fibromyalgia syndrome.

Authors:  Lieven Annemans; Katell Le Lay; Charles Taïeb
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Traditional Chinese Medicine for Fibromyalgia.

Authors:  Scott Mist; Cheryl Wright; Kim D Jones; James W Carson; Jean Shih
Journal:  Pract Pain Manag       Date:  2010-09-01

4.  Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.

Authors:  Nicole M Marlow; Kit N Simpson; Ivana A Vaughn; Ara Jo; James S Zoller; Edward B Short
Journal:  Pain Pract       Date:  2017-05-28       Impact factor: 3.183

5.  Classifying Fibromyalgia Syndrome as a Mental Disorder?-An Ambulatory Assessment Study.

Authors:  Kristina Klaus; Susanne Fischer; Johanna M Doerr; Urs M Nater; Ricarda Mewes
Journal:  Int J Behav Med       Date:  2017-04

6.  The relevance of depressive symptoms and social support to disability in women with multiple sclerosis or fibromyalgia.

Authors:  Lorraine J Phillips; Alexa K Stuifbergen
Journal:  Int J Rehabil Res       Date:  2010-06       Impact factor: 1.479

7.  Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.

Authors:  Sebastian Straube; R Andrew Moore; Jocelyn Paine; Sheena Derry; Ceri J Phillips; Ernst Hallier; Henry J McQuay
Journal:  BMC Musculoskelet Disord       Date:  2011-06-03       Impact factor: 2.362

Review 8.  Fibromyalgia and disability adjudication: no simple solutions to a complex problem.

Authors:  Manfred Harth; Warren R Nielson
Journal:  Pain Res Manag       Date:  2014 Nov-Dec       Impact factor: 3.037

9.  Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials.

Authors:  Ernest H S Choy; Philip J Mease; Daniel K Kajdasz; Madelaine M Wohlreich; Paul Crits-Christoph; Daniel J Walker; Amy S Chappell
Journal:  Clin Rheumatol       Date:  2009-06-18       Impact factor: 2.980

10.  Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia.

Authors:  X Peng; P Sun; D Novick; J Andrews; S Sun
Journal:  J Pain Res       Date:  2014-01-09       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.